Sildenafil Tablet, Film Coated
Product Images NDC 72162-2363

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 72162-2363). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Sildenafil showing its molecular arrangement with a piperazine ring, sulfonamide group, and other functional groups typical of the active ingredient.*
FDA Label Image

Camber1 (Camber1)

Camber1 (Camber1)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A chart displaying fold changes in area under the curve (AUC) and maximum concentration (Cmax) for Sildenafil when coadministered with various interacting drugs, including Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir. The chart includes recommendations on dose adjustments, noting 'No dose adjustment' for most drugs except Ritonavir, where coadministration is not recommended.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A chart showing fold change and 90% confidence intervals of pharmacokinetic parameters (AUC, Cmax, INR, bleeding time) for various interacting drugs with sildenafil compared to the interacting drug alone. The chart includes recommendations on dose adjustment or coadministration for drugs like acenocoumarol, aspirin, atorvastatin, bosentan, doxazosin, ethinylestradiol, levonorgestrel, phenprocoumon, ritonavir, saquinavir, and tolbutamide.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line chart with error bars depicting change from baseline in meters over a 12-week study period. The x-axis represents weeks (4, 8, 12) and the y-axis shows change from baseline in meters. The chart compares three groups: Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, illustrating efficacy over time with greater improvements noted at higher Sildenafil doses.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A forest plot showing placebo-corrected changes in 6-minute walk distance for Sildenafil 20 mg TID by various subgroups, including baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary artery pressure, and pulmonary vascular resistance index. The plot compares Sildenafil to placebo, with data points and confidence intervals for each subgroup.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A survival curve chart depicting the percentage of subjects without a clinically worsening event over time, measured in days from randomization. Two lines are shown: a solid line for the placebo group and a dashed line for the sildenafil group, illustrating a higher percentage without worsening in the sildenafil group across the duration up to 112 days.*
FDA Label Image

Label (Lbl721622363)

Label (Lbl721622363)
Label for Sildenafil Tablets, USP 20 mg, film-coated oral tablets. The label shows a 90-tablet count. It is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Hetero Labs Limited. The label includes storage instructions, dosage references, and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.